Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.33 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417448 | 1.00 | TDP1 (0.44) | TDP1ALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL12794060 | 0.87 | TDP1 (0.39) | TDP1 | |
| SCHEMBL248888 | 0.85 | TDP1 (0.40) | TDP1 | |
| SCHEMBL29899133 | 0.84 | TDP1 (0.43) | TDP1ALDH1A1PKM | |
| SCHEMBL16701835 | 0.84 | TDP1 (0.43) | TDP1ALDH1A1PKM | |
| SCHEMBL7673909 | 0.84 | ALDH1A1 (0.43) | TDP1ALDH1A1MAPT | |
| SCHEMBL16701782 | 0.82 | TDP1 (0.41) | TDP1ALDH1A1PKM | |
| SCHEMBL29919207 | 0.82 | TDP1 (0.41) | TDP1ALDH1A1PKM | |
| SCHEMBL21749477 | 0.82 | TDP1 (0.41) | TDP1ALDH1A1PKMLMNAKMT2A | |
| SCHEMBL31226156 | 0.82 | TDP1 (0.41) | TDP1ALDH1A1PKMLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805005-B | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3840755-B1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2025-07-24 | — | — | US | disclosed |
| US-20250145595-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2025-05-08 | — | — | US | disclosed |
| WO-2025062334-A1 | 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZENESULFONAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER | BEIGENE SWITZERLAND GMBH (CH) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025036275-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2025-02-20 | — | — | WO | disclosed |
| CN-119462517-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4140998-B1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | HENAN SELKIN BIOMEDICAL TECH CO LTD (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-118541365-A | Antagonists of muscarinic acetylcholine receptor M4 | 范德堡大学 | 2024-08-23 | — | — | CN | disclosed |
| US-20240228468-A1 | N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| WO-1999067245-A1 | A SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVE, PHARMACEUTICAL COMPOSITIONS MADE THEREFROM | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-29 | — | — | WO | disclosed |
| EP-0781283-A1 | TRIAZOLOPYRIDAZINES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Takeda Chemical Industries, Ltd. (JP) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008496-A1 | TRIAZOLOPYRIDAZINES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-21 | — | — | WO | disclosed |
| US-5482939-A | ANTI-PLATELET ACTIVATING FACTOR ACTIVITIES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| EP-0208431-B1 | FUNGICIDAL PYRIDAZINES | ELI LILLY AND COMPANY (US) | 1990-07-11 | — | — | EP | disclosed |
| US-4791110-A | FOR PHYCOMYCETES ON PLANTS | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0208431-A1 | Fungicidal pyridazines | ELI LILLY AND COMPANY (US) | 1987-01-14 | — | — | EP | disclosed |
| US-4628088-A | Preparation of substituted pyridazines | ELI LILLY AND COMPANY (US) | 1986-12-09 | — | — | US | disclosed |
| US-4604127-A | CONTACTING VEGETATION, SOIL OR AQUATIC PLANTS; CORN | ELI LILLY AND COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0169050-A2 | Pyridazinylimidazolidinone compounds | ELI LILLY AND COMPANY (US) | 1986-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228468-A1 | N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | CHRM5, CHRM1, CHRM2 | TDP1 311/4885ALDH1A1 1704/4885SMN1; SMN2 367/4885 |
| US-20250145595-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | TDP1 2543/4885ALDH1A1 1885/4885SMN1; SMN2 2843/4885 |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | TDP1 2139/4885ALDH1A1 3553/4885SMN1; SMN2 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.